Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01135277 · ClinicalTrials.gov registry record

Immune Suppression and Ventilator Associated Pneumonias

A clinical trial of Sepsis, sponsored by Matthew Exline.

Completed
Registry status
50
Enrollment target
1
Study location

NCT01135277 is a study of Sepsis that has completed, run by Matthew Exline. The registered enrollment target is 50 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01135277, a study of Sepsis, has completed, sponsored by Matthew Exline.

COMPLETED
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

Patients in the ICU are already predisposed to nosocomial infections, which are both costly and potentially life threatening, and it appears that the immune paralysis of sepsis may put these patients at greater risk for secondary infections, though this has not been proven conclusively. One measure of this sepsis-induced immune suppression is monocyte deactivation. The investigators hypothesize that, as a cornerstone of the monocytic innate immune response to infection, the inflammasome is critical to monocyte function during sepsis.

Conditions Studied

Study Locations (1)

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2010-02
Est. Completion 2012-11

Sponsor

Matthew Exline

1 total trials

What the Registry Record Tells You About NCT01135277

The ClinicalTrials.gov registry entry for NCT01135277 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The listed sponsor is Matthew Exline, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 0 interventions.

NCT01135277 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT01135277 about?

NCT01135277 is a clinical study titled "Immune Suppression and Ventilator Associated Pneumonias". Patients in the ICU are already predisposed to nosocomial infections, which are both costly and potentially life threatening, and it appears that the immune paralysis of sepsis may put these patients at greater risk for secondary infections, though this has not been proven conclusively. One measure ...

What is the current status of trial NCT01135277?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2010-02. Estimated completion is 2012-11.

What conditions does trial NCT01135277 study?

This clinical trial studies the following conditions: Sepsis.

Who is sponsoring clinical trial NCT01135277?

This trial is sponsored by Matthew Exline, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01135277 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.